CVS Health (CVS) Investor Day 2025 summary

Strategic vision and transformation

• Committed to becoming America's most trusted healthcare company by simplifying care, improving access, affordability, and outcomes through integrated pharmacy, insurance, and care delivery businesses, and leveraging technology and digital solutions.

• Executed a major leadership overhaul, exited non-core businesses, and invested $20 billion over 10 years in technology to enable growth and operational excellence.

• Four strategic pillars: best-in-class execution in core businesses, transforming consumer experiences, partnering with providers, and leveraging enterprise capabilities through technology.

• Launched an Open Consumer Engagement Platform, integrating digital and in-person experiences, built as an AI-native product, with commercialization targeted for 2026.

• Focused on building trust and engagement with 185 million consumers, leveraging a national footprint and omnichannel presence.

Financial guidance and performance outlook

• Raised 2025 adjusted EPS guidance to $6.60–$6.70 and revenue to at least $400 billion, with 2026 guidance of $7.00–$7.20 adjusted EPS and at least $400 billion in revenue.

• Projecting 2026 adjusted operating income of $15.07–$15.41 billion and cash flow from operations of at least $10 billion.

• Targeting mid-teens adjusted EPS CAGR through 2028, driven by diversified businesses, margin recovery, and innovation.

• Expecting $55–$60 billion in deployable cash from 2026 to 2028, prioritizing organic growth, dividends, deleveraging, and eventual share repurchases.

• Guidance excludes potential upside from the new open platform, which is seen as a source of outperformance.

Business segment developments

• Health Care Benefits/Aetna: Achieved $2.5 billion AOI improvement in 2025, targeting further $1.7 billion for 2026, with focus on margin recovery and Medicare Advantage and Medicaid.

• Health Care Delivery: Oak Street Health shifted from rapid expansion to margin improvement, enhancing Signify Health and MinuteClinic offerings, targeting mid- to high-single-digit margins long-term.

• Pharmacy Services/Caremark PBM: Transitioning 85% of customers to acquisition cost-based pricing by 2026, leading with TrueCost for transparency and stable margins; specialty pharmacy remains a growth driver.

• Pharmacy & Consumer Wellness/Retail pharmacy: Reversed negative earnings trajectory, now projecting at least flat annual earnings, supported by CostVantage pricing, technology investments, and omnichannel experiences.

• Technology: AI and automation deployed across clinical, service, and pharmacy operations, generating over $1 billion in operating efficiencies for reinvestment.